Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Clinical Impact of RANK Signalling in Ovarian Cancer.

Wieser V, Sprung S, Tsibulak I, Haybaeck J, Hackl H, Fiegl H, Marth C, Zeimet AG.

Cancers (Basel). 2019 Jun 8;11(6). pii: E791. doi: 10.3390/cancers11060791.

2.

Ovarian Cancer Stem Cell Heterogeneity.

Hatina J, Boesch M, Sopper S, Kripnerova M, Wolf D, Reimer D, Marth C, Zeimet AG.

Adv Exp Med Biol. 2019;1139:201-221. doi: 10.1007/978-3-030-14366-4_12.

PMID:
31134503
3.

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.

Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ; TRINOVA-3/ENGOT-ov2/GOG-3001 investigators.

Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.

PMID:
31076365
4.

Contralateral prophylactic mastectomy in women with breast cancer without a family history or genetic predisposition : Consensus statement from the Austrian Gynecologic Oncology Working Group of the Austrian Society of Obstetrics and Gynecology.

Bjelic-Radisic V, Singer C, Tamussino K, Kölbl H, Petru E, Volgger B, Polterauer S, Oppelt P, Sevelda P, Bogner G, Marth C; Austrian Gynecologic Oncology Working Group.

Wien Klin Wochenschr. 2019 May;131(9-10):233-236. doi: 10.1007/s00508-019-1468-7. Epub 2019 Mar 18.

PMID:
30887224
5.

NADPH oxidase 4 expression in the normal endometrium and in endometrial cancer.

Degasper C, Brunner A, Sampson N, Tsibulak I, Wieser V, Welponer H, Marth C, Fiegl H, Zeimet AG.

Tumour Biol. 2019 Feb;41(2):1010428319830002. doi: 10.1177/1010428319830002.

PMID:
30813866
6.

A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim JW, Raspagliesi F, Lampe B, Aletti G, Meier W, Cibula D, Mustea A, Mahner S, Runnebaum IB, Schmalfeldt B, Burges A, Kimmig R, Scambia G, Greggi S, Hilpert F, Hasenburg A, Hillemanns P, Giorda G, von Leffern I, Schade-Brittinger C, Wagner U, du Bois A.

N Engl J Med. 2019 Feb 28;380(9):822-832. doi: 10.1056/NEJMoa1808424.

PMID:
30811909
7.

Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Gnant M, Pfeiler G, Steger GG, Egle D, Greil R, Fitzal F, Wette V, Balic M, Haslbauer F, Melbinger-Zeinitzer E, Bjelic-Radisic V, Jakesz R, Marth C, Sevelda P, Mlineritsch B, Exner R, Fesl C, Frantal S, Singer CF; Austrian Breast and Colorectal Cancer Study Group.

Lancet Oncol. 2019 Mar;20(3):339-351. doi: 10.1016/S1470-2045(18)30862-3. Epub 2019 Feb 19.

PMID:
30795951
8.

Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.

Wieser V, Tsibulak I, Degasper C, Welponer H, Leitner K, Parson W, Zeimet AG, Marth C, Fiegl H.

Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.

9.

Joint Guideline of the OEGGG, AGO, AGK and ÖGZ on the Diagnosis and Treatment of Cervical Intraepithelial Neoplasia and Appropriate Procedures When Cytological Specimens Are Unsatisfactory.

Reich O, Braune G, Eppel W, Fiedler T, Graf A, Hefler L, Joura E, Kölbl H, Marth C, Pokieser W, Regitnig P, Reinthaller A, Tamussino K, Widschwendter A, Zeimet A, Kohlberger P.

Geburtshilfe Frauenheilkd. 2018 Dec;78(12):1232-1244. doi: 10.1055/a-0764-4875. Epub 2018 Dec 14.

10.

Immunotherapy in ovarian cancer: fake news or the real deal?

Marth C, Wieser V, Tsibulak I, Zeimet AG.

Int J Gynecol Cancer. 2019 Jan;29(1):201-211. doi: 10.1136/ijgc-2018-000011. Review.

PMID:
30640705
11.

Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects.

Piovano E, Ferrero A, Zola P, Marth C, Mirza MR, Lindemann K.

Int J Gynecol Cancer. 2019 Jan;29(1):181-187. doi: 10.1136/ijgc-2018-000021.

PMID:
30640702
12.

Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.

Marth C.

Expert Rev Anticancer Ther. 2018 Oct;18(sup1):19-22. doi: 10.1080/14737140.2018.1513793.

PMID:
30223697
13.

A Copper-Mediated Conjugate Addition Approach to Analogues of Aconitine-Type Diterpenoid Alkaloids.

Doering NA, Kou KGM, Norseeda K, Lee JC, Marth CJ, Gallego GM, Sarpong R.

J Org Chem. 2018 Oct 19;83(20):12911-12920. doi: 10.1021/acs.joc.8b01967. Epub 2018 Sep 28.

14.

BRCA1 and BRCA2 mRNA-expression prove to be of clinical impact in ovarian cancer.

Tsibulak I, Wieser V, Degasper C, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Marth C, Fiegl H, Zeimet AG.

Br J Cancer. 2018 Sep;119(6):683-692. doi: 10.1038/s41416-018-0217-4. Epub 2018 Aug 15.

PMID:
30111871
15.

Evaluation of Vav3.1 as prognostic marker in endometrial cancer.

Boesch M, Sopper S, Marth C, Fiegl H, Wiedemair A, Rössler J, Hatina J, Wolf D, Reimer D, Zeimet AG.

J Cancer Res Clin Oncol. 2018 Oct;144(10):2067-2076. doi: 10.1007/s00432-018-2725-2. Epub 2018 Aug 6.

16.

Treatment of Retained Fetal Membranes in the Mare-A Practitioner Survey.

Warnakulasooriya DN, Marth CD, McLeod JA, Hanlon DW, Krekeler N.

Front Vet Sci. 2018 Jun 19;5:128. doi: 10.3389/fvets.2018.00128. eCollection 2018.

17.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Supplement_4):iv262. doi: 10.1093/annonc/mdy160. No abstract available.

PMID:
29741577
18.

BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.

Wieser V, Gaugg I, Fleischer M, Shivalingaiah G, Wenzel S, Sprung S, Lax SF, Zeimet AG, Fiegl H, Marth C.

Oncotarget. 2018 Apr 3;9(25):17501-17511. doi: 10.18632/oncotarget.24770. eCollection 2018 Apr 3.

19.
20.

The use of PIPAC (pressurized intraperitoneal aerosol chemotherapy) in gynecological oncology: a statement by the "Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR)", the Swiss and Austrian AGO, and the North-Eastern German Society of Gynaecologic Oncology.

Dueckelmann AM, Fink D, Harter P, Heinzelmann V, Marth C, Mueller M, Reinthaller A, Tamussino K, Wimberger P, Sehouli J.

Arch Gynecol Obstet. 2018 Apr;297(4):837-846. doi: 10.1007/s00404-018-4673-0. Epub 2018 Jan 22. Review. Erratum in: Arch Gynecol Obstet. 2018 Feb 14;:.

PMID:
29356953
21.

Front-line therapy of advanced epithelial ovarian cancer: standard treatment.

Marth C, Reimer D, Zeimet AG.

Ann Oncol. 2017 Nov 1;28(suppl_8):viii36-viii39. doi: 10.1093/annonc/mdx450. Review.

PMID:
29232473
22.

Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically relevant in predicting prognosis and platinum-response.

Reimer D, Boesch M, Wolf D, Marth C, Sopper S, Hatina J, Altevogt P, Parson W, Hackl H, Zeimet AG.

Int J Cancer. 2018 Apr 15;142(8):1640-1651. doi: 10.1002/ijc.31186. Epub 2017 Dec 14.

23.

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial.

Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators.

Lancet Oncol. 2018 Jan;19(1):127-138. doi: 10.1016/S1470-2045(17)30715-5. Epub 2017 Nov 17.

PMID:
29158011
24.

Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

Jahn B, Arvandi M, Rochau U, Fiegl H, Goebel G, Marth C, Siebert U.

J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.

PMID:
29091014
25.

Platinum or nonplatinum in recurrent ovarian cancer: that is the question.

Poveda A, Marth C.

Future Oncol. 2017 Oct;13(23s):11-16. doi: 10.2217/fon-2017-0317. Epub 2017 Oct 11. Review.

PMID:
29020823
26.

Managing relapsed ovarian cancer in a rapidly evolving landscape.

Poveda A, Marth C.

Future Oncol. 2017 Oct;13(23s):1. doi: 10.2217/fon-2017-0315. Epub 2017 Oct 11. No abstract available.

PMID:
29020820
27.

Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N; ESMO Guidelines Committee.

Ann Oncol. 2017 Jul 1;28(suppl_4):iv72-iv83. doi: 10.1093/annonc/mdx220. No abstract available.

PMID:
28881916
28.

A Unifying Synthesis Approach to the C18-, C19-, and C20-Diterpenoid Alkaloids.

Kou KGM, Kulyk S, Marth CJ, Lee JC, Doering NA, Li BX, Gallego GM, Lebold TP, Sarpong R.

J Am Chem Soc. 2017 Oct 4;139(39):13882-13896. doi: 10.1021/jacs.7b07706. Epub 2017 Sep 20.

29.

European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, duBois A.

Int J Gynecol Cancer. 2017 Sep;27(7):1534-1542. doi: 10.1097/IGC.0000000000001041.

PMID:
30814245
30.

Innate immune genes in persistent mating-induced endometritis in horses.

Marth CD, Firestone SM, Hanlon D, Glenton LY, Browning GF, Young ND, Krekeler N.

Reprod Fertil Dev. 2018 Mar;30(3):533-545. doi: 10.1071/RD17157.

PMID:
28834688
31.

AGO Austria recommendation on screening and diagnosis of Lynch syndrome (LS).

Zeimet AG, Mori H, Petru E, Polterauer S, Reinthaller A, Schauer C, Scholl-Firon T, Singer C, Wimmer K, Zschocke J, Marth C.

Arch Gynecol Obstet. 2017 Jul;296(1):123-127. doi: 10.1007/s00404-017-4392-y. Epub 2017 May 16.

32.

Reduction in advanced breast cancer after introduction of a mammography screening program in Tyrol/Austria.

Oberaigner W, Geiger-Gritsch S, Edlinger M, Daniaux M, Knapp R, Hubalek M, Siebert U, Marth C, Buchberger W.

Breast. 2017 Jun;33:178-182. doi: 10.1016/j.breast.2017.04.002. Epub 2017 Apr 15.

PMID:
28419909
33.

L1CAM and HER2 Expression in Early Endometrioid Uterine Cancer.

Abdel Azim S, Sprung S, Mutz-Dehbalaie I, Fessler S, Zeimet AG, Marth C.

Int J Gynecol Pathol. 2017 Jul;36(4):356-363. doi: 10.1097/PGP.0000000000000338.

PMID:
28221216
34.

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.

McGee J, Bookman M, Harter P, Marth C, McNeish I, Moore KN, Poveda A, Hilpert F, Hasegawa K, Bacon M, Gatsonis C, Brand A, Kridelka F, Berek J, Ottevanger N, Levy T, Silverberg S, Kim BG, Hirte H, Okamoto A, Stuart G, Ochiai K; participants of the 5th Ovarian Cancer Consensus Conference.

Ann Oncol. 2017 Apr 1;28(4):702-710. doi: 10.1093/annonc/mdx010.

PMID:
28119296
35.

Incidental (Prophylactic) Salpingectomy at Benign Gynecologic Surgery and Cesarean Section: a Survey of Practice in Austria.

Potz FL, Tomasch G, Polterauer S, Laky R, Marth C, Tamussino K.

Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1325-1329. doi: 10.1055/s-0042-116493.

36.

ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer.

Marth C, Vergote I, Scambia G, Oberaigner W, Clamp A, Berger R, Kurzeder C, Colombo N, Vuylsteke P, Lorusso D, Hall M, Renard V, Pignata S, Kristeleit R, Altintas S, Rustin G, Wenham RM, Mirza MR, Fong PC, Oza A, Monk BJ, Ma H, Vogl FD, Bach BA.

Eur J Cancer. 2017 Jan;70:111-121. doi: 10.1016/j.ejca.2016.09.004. Epub 2016 Dec 1.

PMID:
27914241
37.

Oestrous cycle-dependent equine uterine immune response to induced infectious endometritis.

Marth CD, Firestone SM, Glenton LY, Browning GF, Young ND, Krekeler N.

Vet Res. 2016 Nov 8;47(1):110.

38.

Current perspectives on recommendations for BRCA genetic testing in ovarian cancer patients.

Vergote I, Banerjee S, Gerdes AM, van Asperen C, Marth C, Vaz F, Ray-Coquard I, Stoppa-Lyonnet D, Gonzalez-Martin A, Sehouli J, Colombo N.

Eur J Cancer. 2016 Dec;69:127-134. doi: 10.1016/j.ejca.2016.10.006. Epub 2016 Nov 4. Review.

PMID:
27821315
39.

Experience with trabectedin + pegylated liposomal doxorubicin for recurrent platinum-sensitive ovarian cancer unsuited to platinum rechallenge.

Colombo N, Hardy-Bessard AC, Ferrandina G, Marth C, Romero I.

Expert Rev Anticancer Ther. 2016 Nov;16(sup1):11-19. Review.

PMID:
27797622
40.

Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.

Notaro S, Reimer D, Duggan-Peer M, Fiegl H, Wiedermair A, Rössler J, Altevogt P, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 28;7(26):40221-40232. doi: 10.18632/oncotarget.9574.

41.

Marked improvement in the success rate of medical management of early pregnancy failure following the implementation of a novel institutional protocol and treatment guidelines: a follow-up study.

Colleselli V, Nell T, Bartosik T, Brunner C, Ciresa-Koenig A, Wildt L, Marth C, Seeber B.

Arch Gynecol Obstet. 2016 Nov;294(6):1265-1272. Epub 2016 Aug 23.

42.

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy.

Dold C, Rodriguez Urbiola C, Wollmann G, Egerer L, Muik A, Bellmann L, Fiegl H, Marth C, Kimpel J, von Laer D.

Mol Ther Oncolytics. 2016 Sep 28;3:16021. eCollection 2016.

43.

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators.

N Engl J Med. 2016 Dec 1;375(22):2154-2164. Epub 2016 Oct 7.

44.

European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B, Harter P, Lundvall L, Marth C, Morice P, Rafii A, Ray-Coquard I, Rockall A, Sessa C, van der Zee A, Vergote I, du Bois A.

Int J Gynecol Cancer. 2016 Sep;26(7):1354-63. doi: 10.1097/IGC.0000000000000767.

PMID:
27648648
45.

Pre-vaccine era cervical human papillomavirus infection among screening population of women in west Austria.

Borena W, Grünberger M, Widschwendter A, Kraxner KH, Marth E, Mayr P, Meier J, Ruth N, Guerrero AT, Marth C, Holm-von Laer D.

BMC Public Health. 2016 Aug 26;16:889. doi: 10.1186/s12889-016-3581-0.

46.

Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2.

Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, Oaknin A, Ray-Coquard I, Provencher DM, Karlan BY, Lhommé C, Richardson G, Rincón DG, Coleman RL, Marth C, Brize A, Fabbro M, Redondo A, Bamias A, Ma H, Vogl FD, Bach BA, Oza AM.

Gynecol Oncol. 2016 Oct;143(1):27-34. doi: 10.1016/j.ygyno.2016.07.112. Epub 2016 Aug 18.

PMID:
27546885
47.

Evaluation of folate receptor 1 (FOLR1) mRNA expression, its specific promoter methylation and global DNA hypomethylation in type I and type II ovarian cancers.

Notaro S, Reimer D, Fiegl H, Schmid G, Wiedemair A, Rössler J, Marth C, Zeimet AG.

BMC Cancer. 2016 Aug 2;16:589. doi: 10.1186/s12885-016-2637-y.

48.

Long-term significance of urinary neopterin in ovarian cancer: a study by the Austrian Association for Gynecologic Oncology (AGO).

Volgger BM, Windbichler GH, Zeimet AG, Graf AH, Bogner G, Angleitner-Boubenizek L, Rohde M, Denison U, Sliutz G, Fuith LC, Fuchs D, Marth C.

Ann Oncol. 2016 Sep;27(9):1740-6. doi: 10.1093/annonc/mdw248. Epub 2016 Jun 29.

PMID:
27358381
49.

Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE).

Kurzeder C, Bover I, Marmé F, Rau J, Pautier P, Colombo N, Lorusso D, Ottevanger P, Bjurberg M, Marth C, Barretina-Ginesta P, Vergote I, Floquet A, Del Campo JM, Mahner S, Bastière-Truchot L, Martin N, Oestergaard MZ, Kiermaier A, Schade-Brittinger C, Polleis S, du Bois A, Gonzalez-Martin A.

J Clin Oncol. 2016 Jul 20;34(21):2516-25. doi: 10.1200/JCO.2015.66.0787. Epub 2016 Jun 6.

PMID:
27269942
50.

Clinical impact of L1CAM expression measured on the transcriptome level in ovarian cancer.

Abdel Azim S, Duggan-Peer M, Sprung S, Reimer D, Fiegl H, Soleiman A, Marth C, Zeimet AG.

Oncotarget. 2016 Jun 14;7(24):37205-37214. doi: 10.18632/oncotarget.9291.

Supplemental Content

Support Center